Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population

Lung Cancer

Volumn 61, Issue 2, 2008, Pages 152-162

  Honma, Helen N ^a   De Capitani, Eduardo M ^a   Perroud Jr , Maurício W ^a   Barbeiro, Aristóteles S ^a   Toro, Ivan F C ^a   Costa, Daniel B ^b   Lima, Carmen S P ^a   Zambon, Lair ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Carcinogenesis; GSTM1; GSTP1; GSTT1; Lung cancer; Metabolism; p53 codon 72 polymorphism; Polymorphism; Susceptibility; Xenobiotics

Indexed keywords

GENOMIC DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD DONOR; BRAZIL; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SMOKING; STATISTICAL SIGNIFICANCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; BRAZIL; CODON; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 47749105357     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.014     Document Type: Article

References (51)

1. Spitz M.R., Wei Q., Dong Q., Amos C.I., and Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomark Prev 12 (2003) 689-698
2. Gresner P., Gromadzinska J., and Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer 57 (2007) 1-25
3. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., and Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14 (1993) 1479-1481
4. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6 (1997) 733-743
5. Kato S., Bowman E.D., Harrington A.M., Blomeke B., and Shields P.G. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 87 (1995) 902-907
6. Pemble S., Schroeder K.R., Spencer S.R., Meyer D.J., Hallier E., Bolt H.M., et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 (1994) 271-276
7. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mut Res 463 (2000) 247-283
8. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and contributions of the isoenzymes to cancer chemoprotection and drug resistance. Crit Ver Biochem Mol Biol 30 (1995) 445-600
9. Antila S., Hirvonen A., Vainio H., Husgafvel-Pursiainen K., Hayes J.D., and Ketterer B. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 53 (1993) 5643-5648
10. Ali-Osman F., Akande O., Antoun G., Mao J.X., and Buolamwini J. Molecular cloning, characterization and expression in Escherichia coli of full-length cDNA of three human glutathione S-transferase pi gene variants. Evidence for differential catalytic activity of the encoded proteins. Biol Chem 272 (1997) 10004-10012
11. Coles B., Yang M., Lang N.P., and Kadlubar F.F. Expression of hGTSP1 alleles in human lung and catalytic activity of the native protein variant towards 1-chloro-2,4-dinitrobenzene, 4-vinylpyridine and (+) antibenzo(a)pyrene-7,8-diol-9,10-oxide. Cancer Lett 156 (2000) 167-175
12. Fan R., Wu M.T., Miller D., Wain J.C., Kelsey K.T., Wiencke J.K., et al. The p53 codon polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 9 (2000) 1037-1042
13. Jin X., Wu X., Roth A., Amos C.I., King T.M., Branch C., et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16 (1995) 2205-2208
14. Murata M., Tagawa M., Kimura M., Kimura H., Watanabe S., and Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17 (1996) 261-264
15. Tagawa M., Murata M., and Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett 128 (1998) 93-99
16. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 (1999) 129-134
17. Woodhead J.L., Fallon R., Figuered H., Longdale J., and Malcom A.D. Alternative methodology of gene diagnosis. In: Davies K. (Ed). Human genetic diseases-a practical approach (1986), Oxford: IRL Press 51-64
18. Saiki R.K., Gelfand D.H., Stoffel S., Scharf S.F., Higuchi R., Horn G.T., et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239 (1988) 487-491
19. Comstock K.E., Sanderson B.J.S., Claifin G., and Hener W.D. GSTT1 gene deletion determined by polymerase chain reaction. Nucl Acid Res 18 (1990) 3670-3676
20. Biros E., Kalina I., Kohut A., Bogyova E., Salagovic J., and Stubna J. Polymorphism of the codon 72 in lung cancer patients. Neoplasma 48 5 (2001) 407-411
21. Arruda V.R., Passos Lima C.S., Grignoli C.R.E., Melo M.B., Lorand-Metze I., Alberto F.L., et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and Theta 1 (GSTT1) gene defects. Eur J Haematol 66 (2001) 1-6
22. Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saúde Pública Rio de Janeiro 18 2 (2002) 357-377
23. Rossini A., Rapozo D.C.M., Amorin L.M.F., Macedo J.M.B., Medina R., Neto J.F.N., et al. Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in Brazilian population. Genet Mol Res 1 3 (2002) 233-240
24. Hosgood H.D., Berndt S.I., and Lan Q. GST genotypes and lung cancer susceptibility in Asian populations with indoor air pollution exposures: a meta-analysis (reviews). Mut Res 636 1-3 (2007) 134-143
25. Taioli E., Gaspari L., Benhamou S., Boffetta P., Brockmoller J., Butkiewicz D., et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 32 (2003) 60-63
26. Sorensen M., Autrup H., Tjonneland A., Overvad K., and Raaschou-Nielsen O. Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int J Cancer 110 (2004) 219-224
27. Sreeja L., Syamala V., Hariharan S., Madhavan J., Devan S.C., and Ankathil R. Possible risk modification by CYP1A1, GSTM1 and GSTT1. Gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 50 (2005) 618-627
28. Saarikoski S.T., Voho A., Reinikainen M., Anttila S., Karjalainen A., Malaveille C., et al. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 77 (1997) 516-521
29. D'Errico A., Malats N., Vineis P., and Boffeta P. Review of studies of selected metabolic polymorphisms and lung cancer. IARC Sci Publ (1999) 323-393
30. Lewis S.J., Cherry N.M., and Niven R.M. GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett 180 (2002) 165-171
31. Nazar-Stewart V., Vaughan T.L., Stapleton P., Loo V.J., Nicol-Blades B., and Eaton D.L. A population based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer. Lung Cancer 40 (2003) 247-258
32. Nelson H.H., Wiencke J.K., Christiani D.C., Cheng T.J., Zuo Z.F., Schwartz B.S., et al. Ethnic differences in the prevalence of the homozygous deleted genotypes of glutathione S-transferase theta. Carcinogenesis 16 (1995) 1243-1245
33. Dai X.D., Lin C.Y., Sun X.W., Shi Y.B., and Lin Y.J. The etiology of lung cancer in nonsmoking females in Habin, China. Lung Cancer 14 1 (1996) S85-S91
34. Lissowska J., Bardin-Mikolajczak A., Fletcher T., Zaridze D., and Szeszemia-Dabrowska H. Lung cancer and indoor pollution from heating and cooking with solid fuels: the IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol 162 (2005) 326-333
35. Sobue T., Suzuki T., Nakayama N., Inubushi T., Matsuda M., Doi O., et al. Association of indoor air pollution and passive smoking with lung cancer in Osaka, Japan. Gan No Rinsho Spec No (1990) 329-333
36. Hernández-Garduño E., Brauer M., Pérez-Neria J., and Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis 8 3 (2004) 377-383
37. Miller D.P., Liu G., De Vivo I., Lynch T.J., Wain J.C., Su L., et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62 15 (2002) 2819-2823
38. Lee J.M., Lee Y.C., Yang S.Y., Shi W.L., Lee C.J., Luh S.P., et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 89 (2000) 458-464
39. Morita S., Yano M., Tsujinara T., Ogawa A., Taniguchi M., Kaneko K., et al. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 79 (1998) 517-520
40. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., and Bell D.A. Human glutathione S-transferees P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis (Lond) 19 (1998) 275-280
41. Jourenkova-Mironova N., Wikman H., Bouchardy C., Voho A., Dayer P., Benhamou S., et al. Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking related lung cancer. Pharmacogenetics 8 (1998) 495-502
42. Kihara M., and Noda K. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Cancer Lett 137 (1999) 53-60
43. Liu G., Miller D.P., Zhou W., Sally W.T., Thurston S.W., Fan R., et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61 (2001) 8718-8722
44. Chen W.C., Tsai F.J., Wu J.Y., Wu H.C., Lu H., and Li C.W. Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 28 (2000) 293-296
45. Bingander R., Sjalander A., Rannug A., Alexandrie A.K., Sundberg M.I., Seidegard J., et al. p53 polymorphism and haplotypes in lung cancer. Carcinogenesis 16 (1995) 2233-2236
46. Wang Y.C., Lee H.S., Chen S.K., Chang Y.Y., and Chen C.Y. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 35 2 (1999) 226-230
47. Hu Y., McDermott M.P., and Ahrendt S.A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11 (2005) 2502-2509
48. Dumont P., Leu J., Pietra A.D., George D., and Murphy. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
49. To-Figueras J., Gene M., Gomez-Catalan J., Galan C., Firvida J., Fuentes M., et al. Glutathione S-transferase M1 and codon 72 p53 polymorphism in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomark Prev 5 (1996) 337-342
50. Mechanic L.E., Bowman E.D., Welsh J.A., Khan M.A., Hagiwana N., Enewold L., et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 16 February (2) (2007) 214-222
51. Wu X., Zhao H., Amos C.I., Shete S., Makan N., Hong W.R., et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94 May (9) (2002) 681-690